AXOGEN INC

Axogen targets 24%+ revenue growth by 2026, driven by breast‑cancer nerve‑repair sales and a new imaging partnership to boost peripheral nerve surgery outcomes.

Discover how Axogen Inc. pioneers nerve repair technology—innovative grafts, connectors, and membranes driving growth in the healthcare equipment sector.

Explore Axogen Inc., a Florida‑based pioneer in peripheral nerve reconstruction tools. Learn how its innovation and Nasdaq presence drive growth, despite volatile markets and a negative P/E.

Axogen Inc. leads in nerve‑repair tech, offering surgical tools for peripheral nerve reconstruction, driving growth amid biotech volatility.

Axogen Inc. announces Q1‑2026 results on April 28, detailing nerve‑repair growth, market performance, and an investor call to discuss future strategies.

Axogen Inc.

Axogen Inc. has appointed Lindsey Hartley as its new Chief Financial Officer, effective May 12, 2025, amidst the company’s Q1 financial results announcement, which showed resilience in a competitive sector.